Contribution of human recombinant Interferon-Alpha 2b treatment in symptomatic and asymptomatic patients with SARS-CoV-2 virus infection
Fuente:
Redalyc
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artículo científico |
| Langue: | en |
| Publié: |
Universidad de Ciencias Médicas de La Habana
2022
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1876485567477186560 |
|---|---|
| author | Cristobal González-Losada |
| author_facet | Cristobal González-Losada |
| contents | Contribution of human recombinant Interferon-Alpha 2b treatment in symptomatic and asymptomatic patients with SARS-CoV-2 virus infection Cristobal González-Losada Anabel González Blanco Luis Gabriel González-Lodeiro Abraham Ismael Beato Canfux Diana del-Barco-García Gerardo Enrique Guillén Nieto Medicina 19 CoV SARS COVID Heberon® Introduction: Subjects with asymptomatic infections are not generally admitted to health care facilities, however, they may benefit from antiviral therapy.Objective: To evaluate the contribution to treatment with combined therapy based on recombinant human interferon alpha 2b + Lopinavir/Ritonavir + Chloroquine versus Lopinavir/Ritonavir + Chloroquine in asymptomatic and symptomatic patients.Material and Methods: An observational study was carried out in patients with a positive diagnosis of COVID-19 from April 1st to July 30th, 2020. From a total of 308 patients treated with interferon + Lopinavir/Ritonavir + Chloroquine, we selected a statistically representative sample of 40 patients using a simple randomization process. As a control group, 27 patients who only received treatment with Lopinavir/Ritonavir + Chloroquine were selected. These patients underwent determinations of anti-SARS-CoV-2 antibodies, determinations of inflammatory markers, and follow-up by RT-PCR to evaluate the time length of negativization. Results: The group treated with interferon had a significantly shorter time to negativization. Patients treated with interferon showed a significant decrease in inflammatory markers at the time of hospital discharge and they had an increase in antibody titers at two and four months after hospital discharge, compared to the group of patients who did not receive interferon. Conclusions: The treatment with exogenous interferon in patients with COVID-19 had a significant contribution to the regulation of the immune response of the patients. 2022 reseña 1729-519X https://www.redalyc.org/articulo.oa?id=180473699007 https://www.redalyc.org/journal/1804/180473699007/ https://www.redalyc.org/journal/1804/180473699007/html/ https://www.redalyc.org/journal/1804/180473699007/180473699007.epub https://www.redalyc.org/journal/1804/180473699007/movil en http://www.redalyc.org/revista.oa?id=1804 Revista Habanera de Ciencias Médicas application/pdf Universidad de Ciencias Médicas de La Habana Revista Habanera de Ciencias Médicas (Cuba) Num.4 Vol.21 |
| format | Artículo científico |
| id | redalyc_180473699007 |
| institution | Redalyc |
| language | en |
| publishDate | 2022 |
| publisher | Universidad de Ciencias Médicas de La Habana |
| spellingShingle | Contribution of human recombinant Interferon-Alpha 2b treatment in symptomatic and asymptomatic patients with SARS-CoV-2 virus infection Cristobal González-Losada Medicina 19 CoV SARS COVID Heberon® Contribution of human recombinant Interferon-Alpha 2b treatment in symptomatic and asymptomatic patients with SARS-CoV-2 virus infection Cristobal González-Losada Anabel González Blanco Luis Gabriel González-Lodeiro Abraham Ismael Beato Canfux Diana del-Barco-García Gerardo Enrique Guillén Nieto Medicina 19 CoV SARS COVID Heberon® Introduction: Subjects with asymptomatic infections are not generally admitted to health care facilities, however, they may benefit from antiviral therapy.Objective: To evaluate the contribution to treatment with combined therapy based on recombinant human interferon alpha 2b + Lopinavir/Ritonavir + Chloroquine versus Lopinavir/Ritonavir + Chloroquine in asymptomatic and symptomatic patients.Material and Methods: An observational study was carried out in patients with a positive diagnosis of COVID-19 from April 1st to July 30th, 2020. From a total of 308 patients treated with interferon + Lopinavir/Ritonavir + Chloroquine, we selected a statistically representative sample of 40 patients using a simple randomization process. As a control group, 27 patients who only received treatment with Lopinavir/Ritonavir + Chloroquine were selected. These patients underwent determinations of anti-SARS-CoV-2 antibodies, determinations of inflammatory markers, and follow-up by RT-PCR to evaluate the time length of negativization. Results: The group treated with interferon had a significantly shorter time to negativization. Patients treated with interferon showed a significant decrease in inflammatory markers at the time of hospital discharge and they had an increase in antibody titers at two and four months after hospital discharge, compared to the group of patients who did not receive interferon. Conclusions: The treatment with exogenous interferon in patients with COVID-19 had a significant contribution to the regulation of the immune response of the patients. 2022 reseña 1729-519X https://www.redalyc.org/articulo.oa?id=180473699007 https://www.redalyc.org/journal/1804/180473699007/ https://www.redalyc.org/journal/1804/180473699007/html/ https://www.redalyc.org/journal/1804/180473699007/180473699007.epub https://www.redalyc.org/journal/1804/180473699007/movil en http://www.redalyc.org/revista.oa?id=1804 Revista Habanera de Ciencias Médicas application/pdf Universidad de Ciencias Médicas de La Habana Revista Habanera de Ciencias Médicas (Cuba) Num.4 Vol.21 |
| title | Contribution of human recombinant Interferon-Alpha 2b treatment in symptomatic and asymptomatic patients with SARS-CoV-2 virus infection |
| topic | Medicina 19 CoV SARS COVID Heberon® |
| url | https://www.redalyc.org/articulo.oa?id=180473699007 https://www.redalyc.org/journal/1804/180473699007/ https://www.redalyc.org/journal/1804/180473699007/html/ https://www.redalyc.org/journal/1804/180473699007/180473699007.epub https://www.redalyc.org/journal/1804/180473699007/movil |